Daniel O. Wilds MBA

Chairman of the Board

Mr. Wilds has more than 40 years of experience as a senior executive and consultant in the health care industry including serving as a consultant to Cynvec since April 2015. He was appointed its Acting CEO in July 2015. Mr. Wilds has served as the President of Healthcare Industry Consulting since 2009. He served from 2009 to 2013 as Executive Chairman of Calcionics Corporation, a virtual company with rights in early-stage cardiovascular disease technology in development at the University of Washington. From 2003 to 2009, he served as President, CEO and Board member of SCOLR Pharma, a specialty pharmaceutical company where he led that company in listing its securities on AMEX, completing successful Phase I, Phase II and Phase III clinical trials and effecting major licensing and strategic partner arrangements. Prior to 2003, Mr. Wilds was the Chairman, President and CEO of Northwest Biotherapeutics, Inc., President and CEO of Shiloov Biotechnologies (USA) Inc., the President and CEO of Adeza Biomedical Corporation, and the President and CEO of Medisence, Inc.

Mr. Wilds began his healthcare career in 1968 at Baxter Healthcare Corporation, where he was employed for 24 years in positions of increasing responsibility including being the President of Baxter Chemotherapy Services, the President and COO of Travenol-Genentech, Inc., a joint venture between Baxter International and Genentech, Inc. and the Vice President, Corporate Alliances. Mr. Wilds received a B.A. in Public Administration from California State University, Los Angeles, and an M.B.A. from Northwestern University’s Kellogg School of Management.

Back to Team

Get in touch

Powered by WordPress. Designed by WooThemes